The American Diabetes Association gratefully recognizes the Pathway to Stop Diabetes corporate sponsors, who cumulatively have contributed more than $47 million to this initiative.
Founding Pathway Sponsors
2018 Visionary Sponsor ($2.5 Million+ annually)
Novo Nordisk Inc.
VIDEO - Dr. Moses
VIDEO - Dr. Kurtzhals
Headquartered in Denmark, Novo Nordisk is a global health care company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy. For more information, visit novonordisk-us.com or follow US activities on Twitter at @novonordiskus.
2018 Accelerator Sponsor ($1.75M - <$2.5M annually)
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services, and devices including innovative blood glucose monitoring systems. Sanofi markets both injectable and oral medications for people with type 1 or type 2 diabetes. For more information, visit: www.sanofi.com.
2018 Initiator Sponsors ($500k - <$1.0M annually)
Eli Lilly and Company Foundation VIDEO
Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers — through medicines and information — for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
For 125 years, Merck has been a global health care leader working to help the world be well. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit www.merck.com.
Corporate Contributors ($100k - <$500k annually)
Founded in 1999, Dexcom, Inc. is transforming diabetes care and management by providing superior continuous glucose monitoring (CGM) technology to help patients and healthcare professionals better manage diabetes. Since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions that are best in class—while empowering our community to take control of diabetes. For more information, visit http://www.dexcom.com/.
Dedicated to addressing the global burden of diabetes by advancing individualized patient care, AstraZeneca is working to develop and commercialize a versatile portfolio of innovative treatment options for diabetes and related metabolic disorders that aim to provide treatment effects beyond glucose control. Find out more about AstraZeneca's commitment to meeting the needs of health care professionals and people with diabetes at www.astrazeneca.com.